TABLE 3. Laboratory variables for CHMS participants with prediabetesa or diabetesb and controls, CHMS cycle 1, 2007–2009.
| Laboratory analyses | Geometric means (95% CI) | ||
|---|---|---|---|
|
Controls
(N = 2054) |
Prediabetesa
(N = 831) |
Diabetesb
(N = 225) |
|
| Urinary arsenic, µg/Lc | 11.5 (9.4–14.1) | 12.5 (10.1–15.4) | 12.9 (9.4–17.7) |
| Urinary arsenic, µg/g creatinined,e | 12.3 (9.8–15.4) | 15.5 (10.9–22.0) | 14.6 (10.5–20.4) |
| Selenium, µg/Lf | 46.9 (45.1–48.7) | 45.8 (43.2–47.9) | 49.9 (44.3–54.7) |
| Fasting glucose, mg/dlg | 4.7 (4.3–5.2) | 5.3 (4.7–5.9) | 6.5 (4.2–10.0) |
| HbA1c, %h | 5.3 (4.9–5.7) | 5.8 (5.3–6.3) | 6.9 (4.8–9.8) |
Abbreviations: CHMS, Canadian Health Measures Survey; CI, confidence interval; HbA1c, glycated hemoglobin.
a
Fasting serum glucose = 100–125 mg/dl (5.6–6.9 mmol/L) or HbA1c 5.7%–6.4%.
b
Fasting serum glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% or self-reported medication use or self-reported health care professional diagnosis.
c
Urinary arsenic not corrected for urinary creatinine.
d
Urinary arsenic corrected for urinary creatinine.
e
Missing data for urinary arsenic corrected for urinary creatinine, n = 39.
f
Missing data for selenium, n = 76.
g
Missing data for fasting glucose, n = 1437.
h
Missing data for HbA1c, n = 106.